Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose and Steady State Pharmacokinetics Study of 9cUAB30 in Healthy Volunteers.

Kolesar JM, Andrews S, Green H, Havighurst TC, Wollmer BW, DeShong K, Laux DE, Krontiras H, Muccio DD, Kim K, Grubbs CJ, House MG, Parnes HL, Heckman-Stoddard BM, Bailey HH.

Cancer Prev Res (Phila). 2019 Sep 4. pii: canprevres.0310.2019. doi: 10.1158/1940-6207.CAPR-19-0310. [Epub ahead of print]

PMID:
31484659
2.

Randomized trial of weight loss in primary breast cancer: Impact on body composition, circulating biomarkers and tumor characteristics.

Demark-Wahnefried W, Rogers LQ, Gibson JT, Harada S, Frugé AD, Oster RA, Grizzle WE, Norian LA, Yang ES, Della Manna D, Jones LW, Azrad M, Krontiras H.

Int J Cancer. 2019 Aug 23. doi: 10.1002/ijc.32637. [Epub ahead of print]

PMID:
31442303
3.

The Impact of Breast Lumpectomy Tray Utilization on Cost Savings.

Malone E, Baldwin J, Richman J, Lancaster R, Krontiras H, Parker C.

J Surg Res. 2019 Jan;233:32-35. doi: 10.1016/j.jss.2018.06.063. Epub 2018 Jul 27.

PMID:
30502265
4.

Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins.

Jones CE, Richman J, Jackson BE, Wallace AS, Krontiras H, Urist MM, Bland KI, Parker CC.

J Surg Res. 2018 Nov;231:36-42. doi: 10.1016/j.jss.2018.05.007. Epub 2018 Jun 1.

PMID:
30278953
5.

Breast Cancer Genetics and Indications for Prophylactic Mastectomy.

Krontiras H, Farmer M, Whatley J.

Surg Clin North Am. 2018 Aug;98(4):677-685. doi: 10.1016/j.suc.2018.03.004. Epub 2018 May 30. Review.

PMID:
30005767
6.

A Structured Compensation Plan Improves But Does Not Erase the Sex Pay Gap in Surgery.

Morris M, Chen H, Heslin MJ, Krontiras H.

Ann Surg. 2018 Sep;268(3):442-448. doi: 10.1097/SLA.0000000000002928.

PMID:
29979249
7.

Select Choices in Benign Breast Disease: An Initiative of the American Society of Breast Surgeons for the American Board of Internal Medicine Choosing Wisely® Campaign.

Rao R, Ludwig K, Bailey L, Berry TS, Buras R, Degnim A, Fayanju OM, Froman J, Golesorkhi N, Greenburg C, Ma AT, Mautner SK, Krontiras H, Sowden M, Wexelman B, Landercasper J.

Ann Surg Oncol. 2018 Oct;25(10):2795-2800. doi: 10.1245/s10434-018-6584-5. Epub 2018 Jul 2.

8.

Benchmarking the American Society of Breast Surgeon Member Performance for More Than a Million Quality Measure-Patient Encounters.

Landercasper J, Fayanju OM, Bailey L, Berry TS, Borgert AJ, Buras R, Chen SL, Degnim AC, Froman J, Gass J, Greenberg C, Mautner SK, Krontiras H, Ramirez LD, Sowden M, Wexelman B, Wilke L, Rao R.

Ann Surg Oncol. 2018 Feb;25(2):501-511. doi: 10.1245/s10434-017-6257-9. Epub 2017 Nov 22.

9.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.

Ma CX, Gao F, Luo J, Northfelt DW, Goetz M, Forero A, Hoog J, Naughton M, Ademuyiwa F, Suresh R, Anderson KS, Margenthaler J, Aft R, Hobday T, Moynihan T, Gillanders W, Cyr A, Eberlein TJ, Hieken T, Krontiras H, Guo Z, Lee MV, Spies NC, Skidmore ZL, Griffith OL, Griffith M, Thomas S, Bumb C, Vij K, Bartlett CH, Koehler M, Al-Kateb H, Sanati S, Ellis MJ.

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

10.

Exploring effects of presurgical weight loss among women with stage 0-II breast cancer: protocol for a randomised controlled feasibility trial.

Tsuruta Y, Rogers LQ, Krontiras H, Grizzle WE, Frugé AD, Oster RA, Umphrey HR, Jones LW, Azrad M, Demark-Wahnefried W.

BMJ Open. 2016 Sep 15;6(9):e012320. doi: 10.1136/bmjopen-2016-012320.

11.

Measures of Appropriateness and Value for Breast Surgeons and Their Patients: The American Society of Breast Surgeons Choosing Wisely (®) Initiative.

Landercasper J, Bailey L, Berry TS, Buras RR, Degnim AC, Fayanju OM, Froman J, Gass J, Greenberg C, Mautner SK, Krontiras H, Rao R, Sowden M, Tjoe JA, Wexelman B, Wilke L, Chen SL.

Ann Surg Oncol. 2016 Oct;23(10):3112-8. doi: 10.1245/s10434-016-5327-8. Epub 2016 Jun 22.

12.

Translation of a Tissue-Selective Rexinoid, UAB30, to the Clinic for Breast Cancer Prevention.

Muccio DD, Atigadda VR, Brouillette WJ, Bland KI, Krontiras H, Grubbs CJ.

Curr Top Med Chem. 2017;17(6):676-695. Review.

PMID:
27320329
13.

Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013.

King TA, Lyman JP, Gonen M, Voci A, De Brot M, Boafo C, Sing AP, Hwang ES, Alvarado MD, Liu MC, Boughey JC, McGuire KP, Van Poznak CH, Jacobs LK, Meszoely IM, Krontiras H, Babiera GV, Norton L, Morrow M, Hudis CA.

J Clin Oncol. 2016 Jul 10;34(20):2359-65. doi: 10.1200/JCO.2015.63.1960. Epub 2016 Mar 21.

14.

Impact of a behavioral weight loss intervention on comorbidities in overweight and obese breast cancer survivors.

Sedjo RL, Flatt SW, Byers T, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Wyatt H, Rock CL.

Support Care Cancer. 2016 Aug;24(8):3285-93. doi: 10.1007/s00520-016-3141-2. Epub 2016 Mar 5.

15.

Quality of life outcomes from the Exercise and Nutrition Enhance Recovery and Good Health for You (ENERGY)-randomized weight loss trial among breast cancer survivors.

Demark-Wahnefried W, Colditz GA, Rock CL, Sedjo RL, Liu J, Wolin KY, Krontiras H, Byers T, Pakiz B, Parker BA, Naughton M, Elias A, Ganz PA; ENERGY Trial Group.

Breast Cancer Res Treat. 2015 Nov;154(2):329-37. doi: 10.1007/s10549-015-3627-5. Epub 2015 Oct 31.

16.

Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.

Atigadda VR, Xia G, Deshpande A, Wu L, Kedishvili N, Smith CD, Krontiras H, Bland KI, Grubbs CJ, Brouillette WJ, Muccio DD.

J Med Chem. 2015 Oct 8;58(19):7763-74. doi: 10.1021/acs.jmedchem.5b00829. Epub 2015 Sep 22.

17.

Results of the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial: A Behavioral Weight Loss Intervention in Overweight or Obese Breast Cancer Survivors.

Rock CL, Flatt SW, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H.

J Clin Oncol. 2015 Oct 1;33(28):3169-76. doi: 10.1200/JCO.2015.61.1095. Epub 2015 Aug 17.

18.

Breast Cancer Risk Reduction, Version 2.2015.

Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.

J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.

PMID:
26150582
19.

TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.

Forero-Torres A, Varley KE, Abramson VG, Li Y, Vaklavas C, Lin NU, Liu MC, Rugo HS, Nanda R, Storniolo AM, Traina TA, Patil S, Van Poznak CH, Nangia JR, Irvin WJ Jr, Krontiras H, De Los Santos JF, Haluska P, Grizzle W, Myers RM, Wolff AC; Translational Breast Cancer Research Consortium (TBCRC).

Clin Cancer Res. 2015 Jun 15;21(12):2722-9. doi: 10.1158/1078-0432.CCR-14-2780. Epub 2015 Mar 16.

20.

Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657).

Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ.

Ann Surg Oncol. 2014 Sep;21(9):2889-96. doi: 10.1245/s10434-014-3721-7. Epub 2014 May 1.

21.

S-(-)equol producing status not associated with breast cancer risk among low isoflavone-consuming US postmenopausal women undergoing a physician-recommended breast biopsy.

Virk-Baker MK, Barnes S, Krontiras H, Nagy TR.

Nutr Res. 2014 Feb;34(2):116-25. doi: 10.1016/j.nutres.2013.12.002. Epub 2013 Dec 18.

22.

What is a clear margin in breast conserving cancer surgery?

Krontiras H, Lancaster RB, Urist MM.

Curr Treat Options Oncol. 2014 Mar;15(1):79-85. doi: 10.1007/s11864-013-0270-4. Review.

PMID:
24395277
23.

Socioeconomic disparities in breast cancer treatment among older women.

White A, Richardson LC, Krontiras H, Pisu M.

J Womens Health (Larchmt). 2014 Apr;23(4):335-41. doi: 10.1089/jwh.2013.4460. Epub 2013 Dec 19.

24.

Comparative evaluation of [(99m)tc]tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two phase 3 trials.

Wallace AM, Han LK, Povoski SP, Deck K, Schneebaum S, Hall NC, Hoh CK, Limmer KK, Krontiras H, Frazier TG, Cox C, Avisar E, Faries M, King DW, Christman L, Vera DR.

Ann Surg Oncol. 2013 Aug;20(8):2590-9. doi: 10.1245/s10434-013-2887-8. Epub 2013 Mar 17.

25.

Harvest for health gardening intervention feasibility study in cancer survivors.

Blair CK, Madan-Swain A, Locher JL, Desmond RA, de Los Santos J, Affuso O, Glover T, Smith K, Carley J, Lipsitz M, Sharma A, Krontiras H, Cantor A, Demark-Wahnefried W.

Acta Oncol. 2013 Aug;52(6):1110-8. doi: 10.3109/0284186X.2013.770165. Epub 2013 Feb 26.

26.

How do I screen patients for breast cancer?

Krontiras H, Bramlett R, Umphrey H.

Curr Treat Options Oncol. 2013 Mar;14(1):88-96. doi: 10.1007/s11864-012-0218-0.

PMID:
23315271
27.

Reducing breast cancer recurrence with weight loss, a vanguard trial: the Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial.

Rock CL, Byers TE, Colditz GA, Demark-Wahnefried W, Ganz PA, Wolin KY, Elias A, Krontiras H, Liu J, Naughton M, Pakiz B, Parker BA, Sedjo RL, Wyatt H; Exercise and Nutrition to Enhance Recovery and Good Health for You (ENERGY) Trial Group.

Contemp Clin Trials. 2013 Mar;34(2):282-95. doi: 10.1016/j.cct.2012.12.003. Epub 2012 Dec 22.

28.

Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.

Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N.

J Clin Oncol. 2012 Sep 10;30(26):3242-9. doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.

29.

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25.

30.

Accuracy of breast magnetic resonance imaging in predicting pathologic response in patients treated with neoadjuvant chemotherapy.

De Los Santos J, Bernreuter W, Keene K, Krontiras H, Carpenter J, Bland K, Cantor A, Forero A.

Clin Breast Cancer. 2011 Oct;11(5):312-9. doi: 10.1016/j.clbc.2011.06.007. Epub 2011 Aug 10.

PMID:
21831721
31.

Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).

Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ; I-SPY TRIAL Investigators.

Breast Cancer Res Treat. 2012 Apr;132(3):871-9. doi: 10.1007/s10549-011-1670-4. Epub 2011 Jul 28.

32.

Image-guided methods for biopsy of suspicious breast lesions.

Vandromme MJ, Umphrey H, Krontiras H.

J Surg Oncol. 2011 Mar 15;103(4):299-305. doi: 10.1002/jso.21795. Review.

PMID:
21337562
33.

A pilot, first-in-human, pharmacokinetic study of 9cUAB30 in healthy volunteers.

Kolesar JM, Hoel R, Pomplun M, Havighurst T, Stublaski J, Wollmer B, Krontiras H, Brouillette W, Muccio D, Kim K, Grubbs CJ, Bailey HE.

Cancer Prev Res (Phila). 2010 Dec;3(12):1565-70. doi: 10.1158/1940-6207.CAPR-10-0149.

34.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Meszoely I, Newman L, Pritchard E, Seewaldt V, Sellin RV, Shapiro CL, Ward JH.

J Natl Compr Canc Netw. 2010 Oct;8(10):1112-46. No abstract available.

PMID:
20971838
35.

Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.

Forero-Torres A, Saleh MN, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith RF, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF.

Clin Breast Cancer. 2010 Aug 1;10(4):275-80. doi: 10.3816/CBC.2010.n.035.

36.

Less-than-standard treatment in rectal cancer patients: which patients are at risk?

Pisu M, Richardson LC, Kim YI, Krontiras H, Martin MY, Salas M, Pollack LA.

J Natl Med Assoc. 2010 Mar;102(3):190-8.

PMID:
20355348
37.

NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2009 Nov;7(10):1060-96. Review. No abstract available. Erratum in: J Natl Compr Canc Netw. 2010 Feb;8(2):xxxvii. Buys, Sandra [corrected to Buys, Saundra]; Yaneeklov, Thomas [corrected to Yankeelov, Thomas].

PMID:
19930975
38.

Specimen radiographs assist in identifying and assessing resection margins of occult breast carcinomas.

Young ES, Hogg DE, Krontiras H, Bernreuter W, Urist M, Bland KI, Chhieng DC.

Breast J. 2009 Sep-Oct;15(5):521-3. doi: 10.1111/j.1524-4741.2009.00770.x. Epub 2009 Jul 13.

PMID:
19624413
39.

Beta-human chorionic gonadotropin production associated with phyllodes tumor of the breast: an unusual paraneoplastic phenomenon.

Reisenbichler ES, Krontiras H, Hameed O.

Breast J. 2009 Sep-Oct;15(5):527-30. doi: 10.1111/j.1524-4741.2009.00772.x. Epub 2009 Jul 13.

PMID:
19624411
40.

The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.

Adams AL, Eltoum I, Krontiras H, Wang W, Chhieng DC.

Breast J. 2008 Mar-Apr;14(2):141-6. doi: 10.1111/j.1524-4741.2007.00544.x. Epub 2008 Jan 31.

PMID:
18248553
41.

Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.

Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, Sanchez V, Sanders ME, Grau AM, Mayer IA, Pestano G, Shyr Y, Muthuswamy S, Calvo B, Krontiras H, Krop IE, Kelley MC, Arteaga CL.

J Clin Oncol. 2008 Feb 20;26(6):897-906. doi: 10.1200/JCO.2007.13.5939. Epub 2008 Jan 7.

PMID:
18180460
42.

Outpatient mastectomy and breast reconstructive surgery.

Bian J, Krontiras H, Allison J.

Ann Surg Oncol. 2008 Apr;15(4):1032-9. doi: 10.1245/s10434-007-9762-4. Epub 2007 Dec 29.

PMID:
18165916
43.

Breast cancer risk reduction.

Bevers TB, Armstrong DK, Arun B, Carlson RW, Cowan KH, Daly MB, Fleming I, Garber JE, Gemignani M, Gradishar WJ, Krontiras H, Kulkarni S, Laronga C, Lawton T, Loftus L, Macdonald DJ, Mahoney MC, Merajver SD, Seewaldt V, Sellin RV, Shapiro CL, Singletary E, Ward JH; National Comprehensive Cancer Network (NCCN).

J Natl Compr Canc Netw. 2007 Sep;5(8):676-701. No abstract available.

PMID:
17927926
44.

Breast cancer screening and diagnosis.

Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2006 May;4(5):480-508. No abstract available.

PMID:
16687096
45.

Nuclear localization of KLF4 is associated with an aggressive phenotype in early-stage breast cancer.

Pandya AY, Talley LI, Frost AR, Fitzgerald TJ, Trivedi V, Chakravarthy M, Chhieng DC, Grizzle WE, Engler JA, Krontiras H, Bland KI, LoBuglio AF, Lobo-Ruppert SM, Ruppert JM.

Clin Cancer Res. 2004 Apr 15;10(8):2709-19.

46.

When is sentinel node biopsy for breast cancer contraindicated?

Krontiras H, Bland KI.

Surg Oncol. 2003 Nov;12(3):207-10. Review.

PMID:
12957625
47.

Axillary lymph node status, but not tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer.

Beenken SW, Urist MM, Zhang Y, Desmond R, Krontiras H, Medina H, Bland KI.

Ann Surg. 2003 May;237(5):732-8; discussion 738-9.

48.

Who should not receive chemotherapy? Data from American databases and trials.

Morrow M, Krontiras H.

J Natl Cancer Inst Monogr. 2001;(30):109-13.

PMID:
11773302
49.

Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53.

Beenken SW, Grizzle WE, Crowe DR, Conner MG, Weiss HL, Sellers MT, Krontiras H, Urist MM, Bland KI.

Ann Surg. 2001 May;233(5):630-8.

50.

Transforming growth factor alpha (TGF-alpha) expression in dysplastic oral leukoplakia: modulation by 13-cis retinoic acid.

Beenken SW, Sellers MT, Huang P, Peters G, Krontiras H, Dixon P, Stockard C, Listinsky C, Grizzle WE.

Head Neck. 1999 Sep;21(6):566-73.

PMID:
10449674

Supplemental Content

Loading ...
Support Center